NCT06537037

Brief Summary

This is the prospective, observational cohort study (Radiogenomics-Urinary), which aims to explore the relationship between the imaging information of urologic cancer patients, tumor microenvironment and the prognosis of urologic cancer patients.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
16mo left

Started Aug 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress59%
Aug 2024Aug 2027

First Submitted

Initial submission to the registry

July 31, 2024

Completed
1 day until next milestone

Study Start

First participant enrolled

August 1, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 5, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2027

Last Updated

August 5, 2024

Status Verified

July 1, 2024

Enrollment Period

3 years

First QC Date

July 31, 2024

Last Update Submit

July 31, 2024

Conditions

Urologic Cancer

Outcome Measures

Primary Outcomes (2)

  • Correlation analysis of sequencing results and body composition

    Conducting correlation analysis between body composition and results of multi-omics sequencing.

    0.5 year

  • Correlation analysis of sequencing results and tumor radiomic features

    Conducting correlation analysis between radiomic features and results of multi-omics sequencing.

    0.5 year

Secondary Outcomes (2)

  • Constructing tumor microenvironment prediction model

    2 years

  • Constructing a multi-dimensional prognostic prediction model

    3 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients treated for urologic cancer

You may qualify if:

  • Patients treated for urologic cancer in Wuhan Union Hospital from August 2024 to August 2027;
  • Aged \> 18 years old;
  • At least one CT scan or MRI scan before treatment;
  • Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

You may not qualify if:

  • Poor image quality;
  • Incomplete clinical data or loss of follow-up;
  • Presence of another primary malignancy other than urologic cancer;
  • Unclear pathological diagnosis。

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Union Hospital，Tongji Medical College，Huazhong University of Science and Technology

Wuhan, Hubei, 430000, China

RECRUITING

MeSH Terms

Conditions

Urologic Neoplasms

Condition Hierarchy (Ancestors)

Urogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesUrologic Diseases

Central Study Contacts

Lian Yang

CONTACT

18986273791yanglian@hust.edu.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 31, 2024

First Posted

August 5, 2024

Study Start

August 1, 2024

Primary Completion (Estimated)

August 1, 2027

Study Completion (Estimated)

August 1, 2027

Last Updated

August 5, 2024

Record last verified: 2024-07

Locations

CN(1)